Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Vertex’s CEO was an AI skeptic. But not anymore.

Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...

5 Tech And Consumer Stocks At Risk Of Steep Declines

Tech stocks and top consumer names are increasingly at risk of steep declines in a slowing economy. Click here to see 5 ...
University of Nevada, Reno

Ask the Professor: Why do we use a sideways 8 to represent infinity?

Professor Raúl Rojas has published a book about how symbols have been used throughout history in mathematics. The work was ...
StockStory.org on MSN

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call

Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively ...
TipRanks on MSN

Vertex Pharmaceuticals initiated with an Outperform at Scotiabank

Scotiabank initiated coverage of Vertex Pharmaceuticals (VRTX) with an Outperform rating and $495 price target Published first on TheFly – the ...